6C8C

Chimeric Pol kappa RIR Rev1 C-terminal domain in complex with JHRE06

  • Classification: REPLICATION
  • Organism(s): Mus musculus
  • Expression System: Escherichia coli
  • Mutation(s): No 

  • Deposited: 2018-01-24 Released: 2019-06-12 
  • Deposition Author(s): Najeeb, J., Zhou, P.
  • Funding Organization(s): National Institutes of Health/National Cancer Institute (NIH/NCI)

Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.50 Å
  • R-Value Free: 0.191 
  • R-Value Work: 0.164 
  • R-Value Observed: 0.165 

wwPDB Validation   3D Report Full Report


Ligand Structure Quality Assessment 


This is version 1.3 of the entry. See complete history


Literature

A Small Molecule Targeting Mutagenic Translesion Synthesis Improves Chemotherapy.

Wojtaszek, J.L.Chatterjee, N.Najeeb, J.Ramos, A.Lee, M.Bian, K.Xue, J.Y.Fenton, B.A.Park, H.Li, D.Hemann, M.T.Hong, J.Walker, G.C.Zhou, P.

(2019) Cell 178: 152

  • DOI: 10.1016/j.cell.2019.05.028
  • Primary Citation of Related Structures:  
    6C59, 6C8C

  • PubMed Abstract: 
  • Intrinsic and acquired drug resistance and induction of secondary malignancies limit successful chemotherapy. Because mutagenic translesion synthesis (TLS) contributes to chemoresistance as well as treatment-induced mutations, targeting TLS is an attractive avenue for improving chemotherapeutics ...

    Intrinsic and acquired drug resistance and induction of secondary malignancies limit successful chemotherapy. Because mutagenic translesion synthesis (TLS) contributes to chemoresistance as well as treatment-induced mutations, targeting TLS is an attractive avenue for improving chemotherapeutics. However, development of small molecules with high specificity and in vivo efficacy for mutagenic TLS has been challenging. Here, we report the discovery of a small-molecule inhibitor, JH-RE-06, that disrupts mutagenic TLS by preventing recruitment of mutagenic POL ζ. Remarkably, JH-RE-06 targets a nearly featureless surface of REV1 that interacts with the REV7 subunit of POL ζ. Binding of JH-RE-06 induces REV1 dimerization, which blocks the REV1-REV7 interaction and POL ζ recruitment. JH-RE-06 inhibits mutagenic TLS and enhances cisplatin-induced toxicity in cultured human and mouse cell lines. Co-administration of JH-RE-06 with cisplatin suppresses the growth of xenograft human melanomas in mice, establishing a framework for developing TLS inhibitors as a novel class of chemotherapy adjuvants.


    Organizational Affiliation

    Department of Biochemistry, Duke University Medical Center, Durham, NC 27710, USA. Electronic address: peizhou@biochem.duke.edu.



Macromolecules
Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChainsSequence LengthOrganismDetailsImage
Chimeric protein of the Pol Kappa RIR helix and the Rev1 C-terminal domainA, B119Mus musculusMutation(s): 0 
Gene Names: PolkDinb1Rev1Rev1l
EC: 2.7.7.7 (PDB Primary Data), 2.7.7 (PDB Primary Data)
UniProt
Find proteins for Q920Q2 (Mus musculus)
Explore Q920Q2 
Go to UniProtKB:  Q920Q2
Find proteins for Q9QUG2 (Mus musculus)
Explore Q9QUG2 
Go to UniProtKB:  Q9QUG2
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupsQ920Q2Q9QUG2
Protein Feature View
Expand
  • Reference Sequence
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
EQ7 (Subject of Investigation/LOI)
Query on EQ7

Download Ideal Coordinates CCD File 
C [auth B]8-chloro-2-[(2,4-dichlorophenyl)amino]-3-(3-methylbutanoyl)-5-nitroquinolin-4(1H)-one
C20 H16 Cl3 N3 O4
LRTXIQCBQIKIOH-UHFFFAOYSA-N
 Ligand Interaction
Binding Affinity Annotations 
IDSourceBinding Affinity
EQ7 Binding MOAD:  6C8C IC50: 780 (nM) from 1 assay(s)
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.50 Å
  • R-Value Free: 0.191 
  • R-Value Work: 0.164 
  • R-Value Observed: 0.165 
  • Space Group: P 21 21 21
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 48.55α = 90
b = 51.02β = 90
c = 98.92γ = 90
Software Package:
Software NamePurpose
PHENIXrefinement
XDSdata reduction
XSCALEdata scaling
PHASERphasing

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment 


Entry History & Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
National Institutes of Health/National Cancer Institute (NIH/NCI)United StatesCA191448

Revision History  (Full details and data files)

  • Version 1.0: 2019-06-12
    Type: Initial release
  • Version 1.1: 2019-06-26
    Changes: Data collection, Database references
  • Version 1.2: 2019-07-10
    Changes: Data collection, Database references
  • Version 1.3: 2019-12-04
    Changes: Author supporting evidence